Related Experiment Video
Updated: May 26, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes
Arianna Carolina Rosa1, Lorenza Rattazzi, Gianluca Miglio
1Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Corso Raffaello 33, 10125 Turin, Italy. ariannacarolina.rosa@unito.it
Objective:
High levels of both angiotensin (Ang) II and tumor necrosis factor (TNF)-α have been implicated in the pathogenesis of glomerular injury by affecting podocytes. The aim of this study was to investigate the Ang II-TNF-α relationship in human podocytes.
Methods:
Immortalized podocytes were exposed to Ang II for 6 days in the absence or presence of either losartan or PD123,319 (both at 100 nM), AT(1) and AT(2) receptor antagonists, respectively.
Results:
Ang II, after at least 72 h of repeated treatment, increased basal TNFA gene expression and cytokine release with a biphasic pattern and maximum response at 10 nM. Losartan dampened the effects of Ang II on TNF-α production throughout the experimental period, demonstrating an AT(1) receptor contribution. PD123,319 affected the second TNF-α production peak, showing also an AT(2) receptor contribution. Moreover, Ang II causes tumor necrosis factor receptor (TNFR) 1 and TNFR2 over-expression in a time-dependent manner. The functional interaction between Ang II and TNF-α was demonstrated when the pro-proliferative effect of Ang II was antagonized by a neutralizing TNF-α antibody.
Conclusions:
Our results show a functional interaction between Ang II and TNF-α and implicate this cytokine as a mediator in Ang II long-term pathoadaptive podocytes changes.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Acute Kidney Injury II: Pathophysiology
Regulation of Angiogenesis and Blood Supply
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension II: Pathophysiology

